SCHEMBL4112362

SCHEMBL4112362

Cc1ccc(NC(=O)Nc2ccc(C)c(F)c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.67
RAB9A P51151 8/20 0.67
KMT2A Q03164 6/20 0.67
MEN1 O00255 5/20 0.67
SMN1; SMN2 Q16637 4/20 0.67
LMNA P02545 2/20 0.67
HTT P42858 2/20 0.67
MAPT P10636 5/20 0.59
STING1 Q86WV6 1/20 0.56
POLB P06746 1/20 0.54
ALDH1A1 P00352 3/20 0.51
HSD17B10 Q99714 2/20 0.51
TP53 P04637 1/20 0.51
GAA P10253 1/20 0.51
ALOX15 P16050 1/20 0.51
GFER P55789 1/20 0.51
FPR2 P25090 1/20 0.51
KIT P10721 1/20 0.50
KDR P35968 1/20 0.50
FLT3 P36888 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4118553 0.93 NPC1 (0.69) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL4112443 0.90 NPC1 (0.71) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL4122903 0.88 NPC1 (0.71) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL4112951 0.88 NPC1 (0.61) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL4105335 0.88 NPC1 (0.64) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL4106913 0.88 RAB9A (0.73) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL4548132 0.87 IDH1 (0.64) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL4112064 0.86 NPC1 (0.62) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL4112024 0.85 NPC1 (0.63) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL4118288 0.85 NPC1 (0.59) NPC1RAB9AKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 NPC1 927/4885RAB9A 815/4885KMT2A 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.